Medical Science Liaison, Reproductive Medicine - Mid-Atlantic at Acadia Pharmaceuticals

Philadelphia, Pennsylvania, United States

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Reproductive MedicineIndustries

Requirements

Advanced degree (PharmD, PhD, MD, DO) required
2+ years of experience in reproductive medicine, maternal health, infertility or related fields
Familiarity with FDA and OIG regulations (training provided to deepen expertise)
Experience with clinical trial design and biostatistics preferred
Strong communication and relationship-building skills
Located within respective territory (Mid-Atlantic: Virginia, Pennsylvania, West Virginia)
Willingness to travel (up to 60%), with flexible scheduling

Responsibilities

Deliver accurate, balanced, and timely scientific information on Ferring products to healthcare professionals and decision-makers
Build strong scientific partnerships with key opinion leaders and academic centers to drive research and education initiatives
Support Phase IV studies and Investigator-Initiated Trials (IITs) from protocol development to completion
Provide ongoing scientific training and field support for Sales and Corporate Account Managers
Monitor medical advancements and competitive activities in reproductive medicine
Represent Ferring at advisory boards, speaker trainings, investigator meetings, and major scientific conferences

Skills

Medical Science Liaison

Reproductive Medicine

Maternal Health

Infertility

FDA Regulations

OIG Regulations

Clinical Trial Design

Biostatistics

Key Opinion Leaders

Investigator-Initiated Trials

Scientific Communication

Acadia Pharmaceuticals

Develops therapies for neurological disorders

About Acadia Pharmaceuticals

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.

Dallas, TexasHeadquarters

1993Year Founded

$813.4MTotal Funding

ACQUISITIONCompany Stage

Biotechnology, HealthcareIndustries

501-1,000Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Risks

Increased competition in CNS drug market may impact Acadia's market share.

Potential clinical trial delays could affect drug approval timelines.

Dependence on partnerships poses risks if collaborations face challenges or dissolve.

Differentiation

Acadia focuses on CNS disorders with unmet medical needs, like Parkinson's and Rett syndrome.

The company has a strong R&D foundation, developing innovative small molecule drugs.

Acadia's strategic partnerships enhance its research capabilities and market reach.

Upsides

Acadia's collaboration with Saniona expands its portfolio with SAN711 for neurological disorders.

Health Canada's approval of Daybue boosts Acadia's presence in the Canadian market.

The rise of personalized medicine aligns with Acadia's targeted therapy approach.

Land your dream remote job 3x faster with AI

Try Jobo Free